Site comparison
Amavita Research vs. Elligo Health Research: which clinical trial site fits your study?
Sponsors comparing Amavita Research with Elligo Health Research are usually deciding between a purpose-built cardiovascular research site and a healthcare-enabling network that brings trials into existing care settings. The models solve different problems.
Amavita Research is a clinical trial site and PET imaging trial partner in North Miami Beach, anchored by a purpose-built, dedicated cardiovascular research site. The senior PI is U.S. TAVR pioneer Dr. William W. O'Neill, National PI on Edwards PARTNER, Protect II, and Protect IV. Every active study is cardiovascular, the affiliated Advanced Cardiovascular of Miami ASC supports interventional procedures on site, and processes are IAOCR GCSA-certified, valid through February 28, 2027.
Elligo Health Research of Austin, Texas describes itself as the largest healthcare-enabling research organization, operating a network of more than 500 sites spanning over 115 hospitals and health systems, with proprietary IntElligo technology for eSource and trial matching. Its model embeds research into healthcare delivery: physicians who do not currently run trials can offer them to their patients through Elligo's infrastructure. For sponsors seeking access to community and health-system patient populations at scale, that reach is the value proposition.
The trade-off is purpose-built versus embedded. An embedded model brings trials to where patients already receive care, which expands access and can accelerate feasibility across many locations. A purpose-built site concentrates research operations - dedicated coordinators, cardiovascular-only SOPs, monitoring infrastructure, and regulatory specialization - at a single address whose entire reason for existing is trial execution.
Amavita's accountability is site-level and personal: one PI team, one BD owner (Nereisy Alonso, COO) with same-business-day response, an anonymized 41-day contract-to-first-patient-in metric, and a Miami patient population that supports FDA Diversity Action Plan enrollment natively. There is no network layer between the sponsor and the people running the protocol.
Sponsors choose the embedded-network model when the program needs broad access across many care settings. They choose the purpose-built specialist when the protocol needs deep cardiovascular execution at a site whose full capacity is pointed at one therapeutic area.
Side-by-side: operating model
Educational summary. We describe the typical healthcare-enabling research network model and do not make claims about any specific institution's current operations.
| Dimension | Amavita Research | Elligo (typical) |
|---|---|---|
| Site type | Purpose-built cardiovascular research site; PET imaging trial partner across therapeutic areas | Healthcare-enabling network (500+ sites, 115+ health systems) |
| Operating model | Dedicated site; 100% of operations are trials | Trials embedded into existing care settings |
| Cardiovascular focus depth | Miami site 100% cardiovascular; PET imaging partnerships in oncology and neurology | Broad therapeutic mix across the network |
| Senior PI profile | TAVR pioneer Dr. William W. O'Neill; National PI on Edwards PARTNER, Protect II, Protect IV | Network of community and health-system physicians |
| Patient sourcing | Active cardiology practice flow + diverse Miami population | EHR-driven matching across partner care settings |
| Sponsor interface | Single owner: Nereisy Alonso, COO | Network operations layer |
| Best fit | Deep cardiovascular execution at one site | Broad patient access across many care settings |
Frequently asked questions
What does 'healthcare-enabling' mean in this context?
It describes a model where a central organization provides the personnel, technology, and processes that let physicians offer clinical trials inside their existing practices and health systems, rather than referring patients to standalone research sites.
When does the embedded-network model win?
When the program needs access to large, distributed patient populations across many care settings, or when the protocol benefits from being offered where patients already receive care.
What is the purpose-built site's advantage?
Concentration of research operations: dedicated coordinators, therapeutic-area SOPs, monitoring infrastructure, and a PI team whose full capacity serves trial execution - with single-owner accountability to the sponsor.
Can sponsors use both models?
Yes. Embedded networks can feed broad access while a purpose-built specialist anchors cardiovascular enrollment depth in a key market like South Florida.
Next step
Schedule a 20-minute capabilities call
One contact. Same-business-day response. Feasibility, budget, contracts, and monitor access all from a single owner.
For a comprehensive sponsor decision framework, read our 2026 site selection guide.
Other comparisons
- Amavita vs. Baptist Health
- Amavita vs. University of Miami
- Amavita vs. Flourish Research
- Amavita vs. Academic Medical Center
- Amavita vs. MCRC
- Amavita vs. SFCRI
- Amavita vs. Altior
- Amavita vs. Multi-Site Network
- Amavita vs. Hospital-Based Research
- Amavita vs. Academic Medical Center (general)
- Amavita vs. Mount Sinai
- Amavita vs. Cleveland Clinic Florida
- Amavita vs. Memorial Cardiac & Vascular
- Amavita vs. Velocity
- Amavita vs. Headlands
- Amavita vs. CIRA